{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:02:06Z","timestamp":1789790526596,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024KY1788"],"award-info":[{"award-number":["2024KY1788"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2025KY1812"],"award-info":[{"award-number":["2025KY1812"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.drup.2026.101469","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T14:04:51Z","timestamp":1786284291000},"page":"101469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["OGT-mediated O-GlcNAcylation of BICD2 drives gemcitabine resistance in pancreatic cancer via accelerating G2\/M cell cycle progression"],"prefix":"10.1016","volume":"89","author":[{"given":"Long","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5394-1686","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.drup.2026.101469_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"19","key":"10.1016\/j.drup.2026.101469_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101469_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.drup.2026.101469_bib4","first-page":"902","article-title":"Pancreatic adenocarcinoma, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Tempero","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"18","key":"10.1016\/j.drup.2026.101469_bib5","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.3390\/ijms20184504","article-title":"Chemoresistance in pancreatic cancer","volume":"20","author":"Zeng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.drup.2026.101469_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/cancers9110157","article-title":"Pancreatic cancer chemoresistance to gemcitabine","volume":"9","author":"Amrutkar","year":"2017","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.drup.2026.101469_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","article-title":"Metabolism of pancreatic cancer: paving the way to better anticancer strategies","volume":"19","author":"Qin","year":"2020","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.drup.2026.101469_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CM9.0000000000002758","article-title":"Pancreatic ductal adenocarcinoma chemoresistance: from metabolism reprogramming to novel treatment","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin. Med. J. (Engl. )"},{"key":"10.1016\/j.drup.2026.101469_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.semcancer.2024.09.002","article-title":"Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems","volume":"106-107","author":"Lencioni","year":"2024","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2026.101469_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2021.08.029","article-title":"Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer","volume":"521","author":"Gu","year":"2021","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.drup.2026.101469_bib11","article-title":"Cholesterol metabolism in pancreatic cancer and associated therapeutic strategies","volume":"1870","author":"Daya","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"},{"issue":"5","key":"10.1016\/j.drup.2026.101469_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.drup.2026.101469_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41419-025-07476-5","article-title":"SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells","volume":"16","author":"Kim","year":"2025","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.drup.2026.101469_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13046-018-0947-4","article-title":"LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer","volume":"37","author":"Feng","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5930","key":"10.1016\/j.drup.2026.101469_bib15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101469_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1146\/annurev-biochem-060608-102511","article-title":"Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease","volume":"80","author":"Hart","year":"2011","journal-title":"Annu. Rev. Biochem."},{"issue":"5","key":"10.1016\/j.drup.2026.101469_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrm3334","article-title":"Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation","volume":"13","author":"Hanover","year":"2012","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"7","key":"10.1016\/j.drup.2026.101469_bib18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nrm.2017.22","article-title":"Protein O-GlcNAcylation: emerging mechanisms and functions","volume":"18","author":"Yang","year":"2017","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.drup.2026.101469_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/or.2025.8952","article-title":"O-GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review)","volume":"54","author":"Charoensuksai","year":"2025","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.drup.2026.101469_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312173","article-title":"The correlation between cellular O-GlcNAcylation and sensitivity to O-GlcNAc inhibitor in colorectal cancer cells","volume":"19","author":"Wongprayoon","year":"2024","journal-title":"PLoS. One"},{"issue":"12","key":"10.1016\/j.drup.2026.101469_bib21","first-page":"3345","article-title":"IFIT3 mediates gemcitabine resistance in pancreatic cancer by regulating VDAC2 O-GlcNAcylation","volume":"27","author":"Wang","year":"2020","journal-title":"Cell. Death Differ."},{"issue":"1","key":"10.1016\/j.drup.2026.101469_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12929-025-01140-y","article-title":"Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer","volume":"32","author":"Jeong","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"3","key":"10.1016\/j.drup.2026.101469_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41388-025-03654-z","article-title":"USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3","volume":"45","author":"Liang","year":"2026","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.drup.2026.101469_bib24","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1038\/s41467-023-38116-1","article-title":"BICD2 phosphorylation regulates dynein function and centrosome separation in G2 and M","volume":"14","author":"Gallis\u00e0-Su\u00f1\u00e9","year":"2023","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.drup.2026.101469_bib25","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1016\/j.cub.2020.05.091","article-title":"Nesprin-2 recruitment of BicD2 to the nuclear envelope controls dynein\/kinesin-mediated neuronal migration in vivo","volume":"30","author":"Gon\u00e7alves","year":"2020","journal-title":"Curr. Biol."},{"issue":"15","key":"10.1016\/j.drup.2026.101469_bib26","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","article-title":"100 years of the Warburg effect: a cancer metabolism endeavor","volume":"187","author":"Fendt","year":"2024","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.drup.2026.101469_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cell.2023.11.022","article-title":"Metabolic regulation of homologous recombination repair by MRE11 lactylation","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.drup.2026.101469_bib28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.cmet.2025.03.006","article-title":"O-GlcNAcylation-mediated endothelial metabolic memory contributes to cardiac damage via small extracellular vesicles","volume":"37","author":"Ding","year":"2025","journal-title":"Cell. Metab."},{"issue":"8","key":"10.1016\/j.drup.2026.101469_bib29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41419-020-02855-6","article-title":"MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1","volume":"11","author":"Bao","year":"2020","journal-title":"Cell. Death Dis."},{"issue":"7900","key":"10.1016\/j.drup.2026.101469_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"issue":"7972","key":"10.1016\/j.drup.2026.101469_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41586-023-06299-8","article-title":"SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity","volume":"620","author":"Guo","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.drup.2026.101469_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010642","article-title":"Role of Nesprin-2 and RanBP2 in BICD2-associated brain developmental disorders","volume":"19","author":"Yi","year":"2023","journal-title":"PLoS Genet."},{"issue":"2","key":"10.1016\/j.drup.2026.101469_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/1574892818666230327134746","article-title":"Chlorogenic acid inhibits proliferation, migration and invasion of pancreatic cancer cells via AKT\/GSK-3\u03b2\/\u03b2-catenin signaling pathway","volume":"19","author":"Chen","year":"2024","journal-title":"Recent. Pat. Anticancer. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101469_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218009","article-title":"Nuclear cGAS mediated replication stress and mitotic catastrophe can overcome gemcitabine resistance","volume":"633","author":"Park","year":"2025","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.drup.2026.101469_bib35","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.7150\/ijbs.91832","article-title":"LncRNAs as nodes for the cross-talk between autophagy and Wnt signaling in pancreatic cancer drug resistance","volume":"20","author":"Huang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"11","key":"10.1016\/j.drup.2026.101469_bib36","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41416-025-03192-1","article-title":"Gemcitabine-induced neutrophil extracellular traps via interleukin-8-CXCR1\/2 pathway promote chemoresistance in pancreatic cancer","volume":"133","author":"Nogi","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.drup.2026.101469_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CM9.0000000000002758","article-title":"Pancreatic ductal adenocarcinoma chemoresistance: from metabolism reprogramming to novel treatment","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin. Med. J."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626001202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626001202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:11:08Z","timestamp":1789787468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626001202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"alternative-id":["S1368764626001202"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101469","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OGT-mediated O-GlcNAcylation of BICD2 drives gemcitabine resistance in pancreatic cancer via accelerating G2\/M cell cycle progression","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101469"}}